Kalev Kask
Chief Executive Officer Adge Pharmaceuticals Inc.
Kalev Kask is the founder and Chief Executive Officer of Adge Pharmaceuticals. He has a rich background in the pharmaceutical industry, having previously led the growth of EGeen International into a global clinical research organization. Dr. Kask’s postgraduate training includes Stockholm University, Stanford University, and the Max-Planck Institute for Medical Research in Heidelberg. He is an inventor on multiple patents and has authored numerous scientific publications. Adge Pharmaceuticals is advancing elocalcitol through clinical trials for obesity and related indications, with a team of experienced drug development experts at its helm.
Seminars
Wednesday 15th July 2026
Correcting Metabolic & Inflammatory Imbalances for Healthy Lifespan
3:00 pm
- Harnessing the SCAP/Insig1 pathway to downregulate SREBP-mediated lipogenesis, providing a direct physiological brake on fat accumulation that remains effective even after the intensive weight-loss phase of GLP-1 therapy is complete
- Utilizing miR-146a upregulation to mitigate hypothalamic senescence and systemic inflammation, restoring metabolic “resilience” and protecting against the weight-gain “rebound” triggered by standard hormonal therapies
- Implementing a low-dose, small molecule regimen that achieves a 55% reduction in visceral fat accumulation, offering an orally-deliverable maintenance solution that secures long-term cardiometabolic health and provides a clear value proposition for global payers
